TPG Capital to acquire Par Pharmaceutical for $1.9 billion
16 Jul 2012
TPG Capital, a US-based private equity firm that focuses on leveraged buyouts, today announced plans to acquire Par Pharmaceutical Cos Inc, for $1.9 billion.
Under the deal that has been approved by Par's board of directors, TPG Capital will pay $50 per share in cash, a premium of around 37 per cent to Par's closing share price on 13 July.
The deal also has a clause that allows Par to solicit superior proposals until 24 August 2012, and if there is no better rival offer, TGP expects the transaction to close in 2012.
New Jersey-based Par is a specialty pharmaceutical company and is the fifth largest generic pharmaceutical company in the US.
It develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.
It also has a branded drugs division, Strativa Pharmaceuticals, which makes vitamin B12 nasal spray and appetite stimulant drugs.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
